zymogen granule protein 16Genealiases: JCLN · JCLN1 · ZG16A
Q-omics provides the consensus-scored ZG16 profile across patient tissues and cancer cell-line models. ZG16 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZG16 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, ZG16 RNA expression shows 9,937 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, COAD, and TGCT as cancer lineages where ZG16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZG16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZG16 survival associations across molecular data types. ZG16 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZG16 RNA expression–survival associations across cancer types. High ZG16 expression shows unfavorable associations in MESO, HNSC, DLBC, BRCA, ESCA and STAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZG16 RNA expression.
This table summarizes ZG16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZG16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZG16 shows lower tumor expression in COAD, LIHC, KICH, THCA, READ and CHOL. The COAD box plot shows higher ZG16 RNA expression in normal versus tumor tissue (log2 FC = −6.445, t-test p < 0.001).
This table shows molecular features associated with ZG16 in patient tissues and cancer cell lines. In patient samples, ZG16 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZG16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LIVER.
